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Abstract
All cells contain proteases which hydrolyse the peptide bonds between amino acids in a protein
backbone. Typically, proteases are prevented from non-specific proteolysis by regulation and by
their physical separation into different sub-cellular compartments; however, this segregation is
not retained during cell lysis, which is the initial step in any protein isolation procedure.
Prevention of proteolysis during protein purification often takes the form of a two-pronged
approach; firstly inhibition of proteolysis in situ, followed by the early separation of the protease
from the protein of interest via chromatographical purification. Protease inhibitors are routinely
used to limit the effect of the proteases before they are physically separated from the protein of
interest via column chromatography. Here, commonly used approaches to reducing or avoiding
proteolysis during protein purification and subsequent chromatography are reviewed.
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1.

Introduction

Protein stability can be defined as “the persistence of molecular integrity or biological function
despite adverse influences or conditions, such as heat or other deleterious conditions” (1). One
of the key deleterious conditions during protein chromatography is the presence of proteolytic
enzymes, referred to as proteases. Proteolysis is the directed degradation of proteins by specific
proteases and occurs ubiquitously in nature as homeostatic levels of proteins in cells are
governed by a fine balance between their rates of synthesis and their rates of degradation (see
Fig. 1). Proteases have been referred to as “Nature’s Swiss Army knife” due to their diverse roles
in protein cleavage (2).
Proteases are employed by all living cells to maintain a particular rate of protein turnover by
continuous degradation and synthesis of proteins. Catabolism of proteins provides a ready pool
of amino acids that can be reused as precursors for protein synthesis. Intracellular proteases
participate in executing correct protein turnover for the cell; for example, in E. coli, the ATPdependent protease La, the lon gene product, is responsible for hydrolysis of abnormal proteins
(3). The turnover of intracellular proteins in eukaryotes is also affected by a pathway involving
ATP-dependent proteases (4).
Issues with proteases are less acute when purification is from a recombinant host such as E. coli
since such hosts have been engineered to minimize proteolysis. Nonetheless, issues can arise that
may be avoided by judicious choice of expression host. Proteins purified directly from “native”
tissues are a different matter and present a far greater challenge. In the latter case the lysis of
subcellular organelles may cause the release of a number of ill defined, damaging proteases. In
this review the term “protein of interest” will be used to denote the target protein, recombinant or
otherwise, to be purified.

[INSERT FIGURE 1 ABOUT HERE]

Originally, proteases were thought to be involved solely in the degradation of unwanted proteins,
but they are now known to take part in a wide range of important signalling and physiological
processes such as angiogenesis, apoptosis and blood clotting (5). The ability of many proteases
to digest proteins at known cleavage sites has given rise to a host of biotechnological
applications for these enzymes (6). Research in this area now employs bioinformatics (7) and
systems biology (8) amongst other tools to investigate the complex interlinked proteome. Based
on this research some proteases are recognised as biomarkers for disease states and have become
the target of therapeutic intervention in an attempt to modulate a variety of signalling pathways
(9).

2.

Protease Classification

Proteases belong to the hydrolase class of enzyme (Enzyme Classification 3.4), which catalyse
the hydrolysis of various bonds with the participation of a water molecule. The proteolytic
process involves the cleavage of peptide bonds that link amino acids together in the polypeptide
chain. Proteases are defined as either exopeptidases or endopeptidases depending on their site of
action (see Table 1). Proteases are also categorised into four major groups according to their
catalytic active site and mode of action (see Table 2). Another classification divides proteases on
the basis of their pH optimum. Thus, acid proteases are optimally active at acid pH values: these
were originally identified in the mammalian stomach as components of digestive juices (e.g.

Chymotrypsin). Neutral proteases and alkaline proteases are optimally active at neutral and
alkaline pH values respectively.

[INSERT TABLE 1 AND 2 HERE]

3. Proteolysis

3.1 Proteolysis during protein purification: prevention is better than cure
Proteases are essential components in all life forms and in normal circumstances proteases are
typically packaged into specialised organelles to minimise the chance of unwanted proteolytic
activity. Within these organelles there are specific regulators associated with each protease,
controlling the action of the protease. Prior to any chromatography step it is necessary to lyse or
disrupt cells to liberate the protein of interest in soluble form. It is at this stage that a protein is
most vulnerable to proteolysis. When cells are disrupted prior to chromatography-based
purification, proteases that are normally located in a different sub-cellular compartments are
separated from their regulator molecules and exposed to the protein of interest, thus increasing
the probability of undesired proteolysis (10). Realistically, it is impossible to remove all
proteases present in a chromatography sample preparation, however, careful selection of host cell
(if protein of choice is recombinantly expressed) or cell type (if the protein of choice is native) in
conjunction with specific sample preparation protocols can reduce unwanted proteolysis during
purification (11). Approaches to reduce proteolysis during heterologous protein expression and
native protein extraction for chromatography purposes will be discussed here by way of
examples.

3.2

Reducing Proteolysis during heterologous protein expression

During the production of recombinant proteins, the protein of interest may be exposed to a host
protease to which it is particularly susceptible. There are many design strategies that can be
enacted to reduce such a potential proteolytic effect. The gram-negative bacterium E. coli is the
most widely used host for heterologous protein expression in both research laboratories and
industry. The approaches below refer to expression in this host, but will apply to other organisms
in many cases.

3.2.1 Use of alternative expression strains:
Simply altering the host strain may reduce proteolysis of recombinant proteins. There are many
commercially available protease deficient strains for heterologous protein expression; for
example E. coli BL21, is deficient in two proteases encoded by the lon (cytoplasmic protease)
and ompT (periplasmic protease) genes, while other strains lack Prc and DnaJ protease genes
(12, see Table 3).

3.2.2 Targeting of expressed protein:
Proteins may be expressed in a subcellular compartment where they are less likely to encounter a
protease. Targeting to the periplasmic space of E. coli, or even extra-cellularly, by use of coexpressed signaling sequences may avoid degradation by cytoplasmic proteases during
expression. This approach, combined with selective cell lysis, will reduce the likelihood of the
expressed protein coming in contact with cellular proteases.

3.2.3 Reduce protein misfolding:
Protein degradation by proteolysis occurs naturally when mis-folded proteins are produced in the
cell. Misfolded proteins are commonly produced during heterologous protein expression and can
occur due to a difference in codon usage between E. coli and the expressed protein’s native
environment. The codon bias may be reduced by using specific cell lines (e.g. OragamiTM or
pRARETM from Novagen), lowering growth temperature (see 13 for an in-depth review) or by
altering the growth medium (e.g. polyol inclusion (14)).

3.2.4 Use of fusion proteins:
Another approach to protect recombinant proteins from unwanted proteolysis is to fuse
them to a protein tag. These tags can improve protein folding and solubility and also act
as a convenient handle for purification. Examples here include proteins fused to
Glutathione-S-Transferase (GST) or Maltose Binding Protein (MBP). Vectors
incorporating such tags are commercially available; GST (pGEX plasmid system from
GE Healthcare) and MBP (pMAL plasmid system from New England Biolabs).

3.2.5 Alternative expression hosts:
If the above approaches fail, it may be necessary to consider expression in another
heterologous host (e.g. another prokaryote, yeast or mammalian cell line). A number of
commercially available expression systems have been developed in recent years (15, 16
and 17).

3.3

Proteolysis reduction during native protein purification

The purification of proteins from cells (plant or animal) other than specialized prokaryotic
expression hosts can be more problematic. In the case of eukaryotic cells, for example, cell lysis
may cause the release of lysosomal proteases that may attack a protein of interest. In this case a
number of basic procedures to minimize protease activity are required.

3.3.1 Source of native protein:
Native protein sources, such as mammalian tissues, often exhibit differing protease levels (e.g.
liver and kidney samples contain a much higher concentration of proteolytic enzymes than
skeletal or cardiac muscle, 18). Careful selection of protein source may sufficiently reduce
protease activity during extraction and purification.

3.3.2 Low temperature lysis:
Cell lysis is normally carried out on ice to keep degradative processes to a minimum. The extract
buffer should also be chilled to 4oC before use.

3.3.3 Work quickly: It is important to prepare a clarified cell extract for purification as quickly as
possible to minimize contact between the protease and the protein of interest. A clarified extract
is normally achieved by centrifugation using a refrigerated centrifuge. It is important to proceed
to the first purification step as quickly as possible after cell lysis and clarification. The initial
purification step should be designed to separate the protein of interest from proteases.

3.3.4 Control of pH:
Typically cell lysis is carried out at neutral or slightly alkaline pH. This will minimize the
activity of acid proteases; however, it will not affect neutral or alkaline proteases.

3.3.5 Lysis buffer additives:
A range of compounds may be added, sequentially or simultaneously, to the lysis buffer to
reduce protease action. Salts may be added to alter the osmotic concentration of buffer, glycerol
(5-15% v/v) and sucrose (2.5 mM) may be added to stabilize proteins. In addition to these
compounds there are a range of specific protease inhibitors that may be added to lysis buffers to
stabilize proteins (see Table 4). Many of these agents are commercially available as inhibitor
cocktails or they can be made in-house (see Table 5 and Section 4.3).

3.3.6 Alternative approaches:
In some cases it may be possible to heat shock an extract to temperatures up to 700C or more;
however, this will only work if the protein of interest is heat stable. The heat shock inactivates
degradative enzymes, such as proteases, while maintaining the activity of the protein of interest.
Another approach is to use salting-out to precipitate and stabilize the protein of interest. In this
process ammonium sulphate is added (slowly, with stirring) up to 70% w/v saturation to render
proteins insoluble. The precipitated proteins may be collected by centrifugation. Many proteins
are surprisingly stable as precipitates and can be stored in this form for extended periods before
being resolubilised by a simple dialysis step.

Once the source of the protein of interest has been optimized, a commonly used approach toward
prevention of further unwanted proteolysis during protein isolation and purification is to include
protease inhibitors during sample preparation, purification, and characterization.

[INSERT TABLE 3 ABOUT HERE]

4.

Protease Inhibition

4.1. Protease Inhibitor Selection and Preparation
Proteolysis avoidance, or reduction, is better than dealing with a protease after it has begun to
act. However, if proteolysis is unavoidable, understanding the protease you are dealing with will
help in choosing alternative protein isolation and purification strategies or, in the worst case,
selecting a suitable inhibitor. One should also consider whether the protease activity is a problem
all of the time, or only during certain conditions (e.g. stressful induction, isolation from cancer
cell lines, see 19). Judicious inhibitor choice will depend on the correct empirical identification
of the protease involved.
The identity of a protease(s) can be determined in several ways, however, the simplest method is
to incubate the sample of choice with a single inhibitor from the group of inhibitors (Serine,
Cysteine, Thiol, Metallo- etc.) listed in Table 2. The degree of proteolysis can be simply
identified from Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS PAGE)
analysis of the protein sample post-inhibitor incubation; increased protein band smearing on the
gel or a change in expected protein size will indicate potential proteolysis. Proteolysis inhibition,
indicated by a maintenance of correct protein size with no protein band smearing after a given

incubation period with inhibitor, will permit the identification of a suitable inhibitor group for
the sample preparation. There are alternative strategies for the specific identification of proteases
including fluorescence labelling (20), substrate tagging (21), zymography (22) and activity based
probes (23); however, these techniques are generally more expensive and labour intensive. The
type of proteolysis encountered in a given tissue sample can be divided into two broad
categories:
Minor hydrolysis: An exopeptidase that cleaves off one, or more, terminal amino acids may
cause little disruption to the integrity or function of a protein. This degree of degradation may go
unnoticed as catalytic activity, for example, may be unchanged. In some cases, significant
cleavage of an enzyme by endopeptidases may occur without loss of activity or function. Such
proteolysis may only be detected as electrophoretic heterogeneity or by Mass Spectroscopy. A
consequence of this hydrolysis where protein activity or function is partially lost may be
extremely difficult to detect.

Catastrophic hydrolysis: In this case hydrolysis is such as to render a protein devoid of activity
or function. The protein may not be detectable by traditional techniques such as activity assay or
using antibody probes. In this case it may be useful to monitor lysates for protease activity using
an appropriate screening assay.

Once the type of protease has been identified, individual inhibitors can be chosen from Table 4
or a typical general-use protease inhibitor mix can be prepared immediately before use from the
stock concentrations outlined in Table 5. Protease inhibitor solutions must be correctly stored
after they have been prepared. Aliquot a stock solution of inhibitor and store it at the correct

temperature (see Table 4) to maintain the properties of the inhibitor. Make small, single use
aliquots to reduce the risk of stock contamination. Ensure that the protease inhibitor/inhibitor
mix is combined with the cell sample immediately prior to cell disruption. If the individual
protease inhibitor/inhibitor mix is to be prepared fresh then it must be used within one hour of
preparation.

[INSERT TABLE FOUR ABOUT HERE]

[INSERT TABLE FIVE ABOUT HERE]

It should be noted that the generic protease inhibitor cocktail outlined here is not guaranteed to
work in all circumstances. The success of any mix will depend on the correct empirical
identification of the protease involved.

4.2

Commercially available Universal Protease Inhibitor Mixes.

There are several types of commercially available “Universal Protease Inhibitors” that may also
be used (e.g. Complete Protease Inhibitor Cocktail Tablets, Roche Applied Science).
Additionally, many companies offer inhibitor panels, such as the Protease Inhibitor Panel
(Sigma Aldrich), which is a cost-effective method for personalized protease cocktail inhibitor
generation (24).

4.3

Supplementary Protease Inhibitor Components.

Additional Inhibitors
If a particular protease is thought to be dominant within a sample preparation, the cocktail mix
may be supplemented with additional specific protease inhibitors (25- 33). Commonly used
specific individual protease inhibitor components are outlined in Table 6.

[INSERT TABLE SIX ABOUT HERE]

Phosphatase inhibitors may also be required since many enzymes are activated by
phosphorylation: hence dephosphorylation must be inhibited if enzyme activity is to be
maintained. Again, an empirical approach is required to identify if a phosphatase inhibitor is
required (see Section 4.1 and Table 7). Protein phosphatases can be divided into two main
groups: protein tyrosine phosphatases and protein serine/threonine phosphatases, which remove
phosphate from proteins (or peptides) containing phosphotyrosine or
phosphoserine/phosphothreonine respectively (34). Inhibitors commonly used include: pBromotetramisole, Cantharidin, Microcystin LR (Ser/Thr Protein Phosphatases and Alkaline
Phosphatase L-Isozymes) and Imidazole, Sodium molybdate, Sodium orthovanadate, Sodium
tartrate (Tyr Protein Phosphatases and Acid and Alkaline Phosphatases, see Table 7). There are
also a number of commercially available Phosphatase Inhibitor Mastermixes (e.g.
PhosphataseArrest™ Phosphatase Inhibitor Cocktail, Geno Technologies Ltd.). These are often
supplied in convenient, ready-to-use 100X solutions that are simply added to the protein
extraction buffer or individual samples. These mixes can be sourced as either broad spectrum
phosphatase inhibitor cocktails or as phosphatase inhibitors for targeting particular set of
phosphatases.

[INSERT TABLE SEVEN ABOUT HERE]

4.4

Supplementary Chemical Compounds including Enzymes.

The addition of supplementary chemical components to disrupt protease activity should be
carefully assessed on a small scale since such components may alter the function/stability of the
protein of interest (see Table 8). Moreover, additional protease inhibitors should be introduced
to the sample with caution since protein modifications, such as alteration of protein charge, may
occur. These alterations may interfere with further protein characterisation studies. For example,
2-mercaptoethanol will reduce the cysteine proteases, but may also unfold target proteins
containing disulphide bridges. Ethylenediamine-tetraacetic acid (EDTA) is included in many
protease inhibitor buffers because metal ions are frequently involved in proteolysis, thus their
removal will impede proteolysis. However, if one is purifying poly-Histidine tagged proteins or
metalloproteins, then the chelating effect of EDTA will dramatically alter purification yields, and
the EDTA should be removed by dialysis or a buffer exchange resin prior to chromatography.
Inclusion of 2 M thiourea may also prevent proteolysis: Castellanos-Serra and Paz-Lago (35)
noted the protease inhibitory effects of its addition in conjunction with its efficiency in
solubilizing proteins. DNase (100 U/mL), although not itself a protease inhibitor, can be
included in the cell lysis buffer as this will serve to reduce the viscosity of the crude lysate. The
reaction is allowed to proceed for 10 min at 4°C in the presence of 10 mM MgCl2.

[INSERT TABLE EIGHT ABOUT HERE]

4.5

Protease Inhibition During Chromatography.

The introduction of contaminating proteases from your own skin, non-sterile water etc. can be
avoided by sterilising all plasticware and by wearing appropriate personal protective equipment.
All buffers should be filter sterilised (0.2 µm) into autoclaved bottles (sterile filtering will not
remove contaminating proteases, but will remove any protease secreting microorganisms).
Additionally, sterile filtration of the protein eluate, once purification is complete, is
recommended.

Cell disruption, as with all other parts of the purification procedure, should take place at 2-8oC.
This temperature will not only reduce the activity of proteases, but will also aid in stabilizing the
target protein (reduction in thermal denaturation). Kulakowska-Bodzon and co-workers (36)
provide an excellent review on protein preparation from various cell types for proteomic work.
In general, all buffers and materials should be pre-chilled to 2-8oC. Rapid purification at this
lower temperature will reduce the risk of unwanted proteolysis. It is advisable not to store such
samples at 2-8oC for more than one day between purification steps, rather store them at -20°C.

Gel filtration (size exclusion chromatography) is often used as the final step in protein
purification where it can be used to desalt and buffer exchange the protein (thus eliminating the
need for dialysis). Contaminating proteases can also be separated from the protein of choice if
there is significant separation between elution peaks for the protease and the protein of choice.
This is the case only where there is a considerable difference between the size of the protease
and the size of the protein of interest. If a multi-step purification strategy is being used, try to
carry out the purification that delivers the best separation between protease and protein of

interest at the beginning. This, however, may not always be feasible, as other factors must be
considered in designing a purification strategy (e.g. physio-chemical properties of the target
protein, cost and time).

5. Proteases in chromatography

5.1

Use of proteases during chromatography

Some purification protocols require the addition of specific proteases. Common examples here
include the use of enterokinase (recognition site D-D-D-K) or TEV protease (recognition site EN-L-Y-F-Q-G) to remove polypeptide and protein purification tags from recombinant proteins.
More recently, designed and non-specific proteolysis during preparative chromatography has
been used to assist in glycoprotein characterisation (37 and 38), lipid protein purification (39)
and antibody profiling (40). In all cases, it is critical to ensure that any protease inhibitor
containing buffer is exchanged, by dialysis or a suitable buffer exchange resin, prior to the
addition of the desired protease.

5.2

Post-Chromatographic Analysis.

Protease inhibition can be either reversible or irreversible. The majority of serine and cysteine
protease inhibitors are irreversible, whereas the aspartic and metalloprotease inhibitors are
reversible. Even when the inhibitors are added at an early stage, they may be lost during

purification and subsequent handling steps, resulting in proteolysis post-chromatography. The
further re-addition of protease inhibitors may therefore be necessary as purification progresses.

Even with increased numbers of purification steps, very few protocols will remove all proteases
from a sample preparation however one can hope to achieve an adequate reduction in the level of
these contaminants. Each purification protocol will have a unique definition of “adequate
protease reduction” based on a number of variables including the activity of the remaining
proteases, further downstream applications of the protein of choice and the cost of further
protease removal. Additional purification steps often result in a reduced final yield, as such the
trade-off between contaminant reduction and yield must be optimised.

An apparently pure protein that gives a single band on a Coomassie-stained SDS-PAGE gel
should be re-analysed over time to ensure minimal protease activity exists in the purified sample.
This may be carried out by simply storing an aliquot of the purified protein solution at room
temperature and analysing samples of this by SDS-PAGE at regular intervals. If the protein is
being degraded (indicated by a smear or a reduced size of the protein of choice), protease
contamination is present and an additional purification step (or supplemental inhibitor addition)
is required.

Care must be taken to rule out the possible loss of enzyme activity due to other destabilizing
factors during protein purification. These other factors include, but are not limited to, thermal
denaturation, oxidative damage and column matrix adherence. Thermal denaturation of proteins
is the decreased stability of a protein caused by extremes of temperature. Thermal denaturation

can be reduced if the purification procedure is carried out at 2-8 oC. All buffers and
chromatography columns/resins should be pre-chilled to 2-8 oC and the purified protein stored at
the correct temperature.
Oxidative damage to proteins can be divided into a number of categories, however improper
disulphide formation is the most pertinent here. Thiol oxidation may be crucial for correct
protein folding. The formation of incorrect intra- or intermolecular disulfides is a detrimental
process that can often result in loss of activity and/or aggregation. Oxidative damage can be
avoided by not exposing the protein of interest to thiol reducing compounds (e.g. βmercaptoethanol) during purification thus maintaining the correct folded state of the protein.
Column matrix adherence is caused by the binding of the protein of interest to the purification
column support material by virtue of its physicochemical properties (e.g. surface charge or
hydrophobicity). Non-specific protein adherence can cause sheer stress damage to the protein
during purification, however this can be circumvented by careful selection of the purification
column (type/grade of glass or plastic) and purification resin.

6.

Conclusion

The presence of proteolytic enzymes can result in target protein degradation during protein
chromatography. Careful selection of source organism/tissue, along with judicious use of
protease inhibitors, can reduce these degrading effects. Commonly used inhibitors are listed here
in tabular format (see Tables 4 and 5), along with supplemental compounds (see Tables 6 and 7)
for easy selection. Protease inhibitors can be added individually or as part of a mix, however,
optimal inhibitor selection is an empirical process.
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Table 1: Broad classification of proteases based on their site of action along a protein chain.
Peptidase Type
Exopeptidase

Endopeptidase

Mode of Action
Hydrolyse the terminal amino acids from
the protein chain. They may act on the
amino, or carboxyl, terminal of the
peptide chain.
Hydrolyse internal peptide bonds of a
protein, common examples here include
trypsin, chymotrypsin, pepsin, and papain

Common Examples
Aminopeptidases and
Carboxypeptidase

Trypsin, Chymotrypsin,
Pepsin, and Papain

Table 2: Broad classification of proteases based on their active site amino acid or metal ion (41).
Protease Type
Serine Protease

Active Site Amino Acid
or Metal Ion
Serine

Cysteine (thiol) Protease

Nucleophilic cysteine thiol

Aspartate Protease

Aspartic Acid (in general,
two highly-conserved
aspartate residues)
Glutamate and Glutamine
dyad.

Glutamate Protease

Threonine Protease

Threonine (commonly
activated by a Histidine)

Asparagine Protease

Asparagine (commonly as
a dyad with an acidic
residue)
Catalysis requires an
active site metal ion (e.g.
zinc or cobalt)

Metalloproteases

Common Examples
Subtilisin (EC 3.4.21.62, an
endopeptidase sourced from Bacillus
subtilis, (42))
Papain (EC 3.4.22.2, an endopeptidase
sourced from Carica papaya, (43))
Plasmepsin (EC 3.4.23.39, an
endopeptidase produced by the
Plasmodium parasite, (44))
Glutamate carboxypeptidase 2
(EC 3.4.17.21, an exopeptidase sourced
from Homo sapiens, (45))
TSP50 peptidase, an endopeptidase
sourced from Homo sapiens, (46)).
MeTr peptidase, an endopeptidase
sourced from Homo sapiens, (47)).
Adamalysin (EC 3.4.24.46, an
endopeptidase from the rattlesnake
Crotalus adamanteus, (48)).

Table 3: Some commercially available protease-deficient E. coli strains that are used to express
recombinant proteins.
Strain Name

Protease Deficiency

Supplier

Deficient in OmpT (an outer
New England Biolabs Inc.
membrane protease that cleaves
between sequential basic amino acids).
Deficient in Lon (a protease that
degrades abnormal/misfolded
New England Biolabs Inc.
proteins).

UT5600

CAG626

CAG597

Stress-induced proteases at high
temperature.

New England Biolabs Inc.

CAG629

Stress-induced proteases at high
temperature and Lon protease.

New England Biolabs Inc.

PR1031

Deficient in DnaJ –a chaperone that
can promote protein degradation.

New England Biolabs Inc.

KS1000

Deficient in Prc (Tsp), a periplasmic
protease.

New England Biolabs Inc.

Rosetta

Deficient in Lon and OmpT.

Novagen

Rosetta-gami B

Deficient in Lon and OmpT.

Novagen

Origami B

Deficient in Lon and OmpT.

Novagen

.

Deficient in Lon and OmpT.

Invitrogen

.

Deficient in Lon and OmpT.

Invitrogen

Deficient in Lon and OmpT.

Invitrogen

BL21 Star (DE3)pLysS
BL21 Star (DE3)
BL21-AI

Table 4: Protease-Inhibitors: Stock Solutions and Storage Conditions.
Inhibitor Activity

Inhibitor

Solvent

Molarity

Storage

Serine

PMSF1

dry methanol or propanol

200 mM

-20oC

Serine

3,4-DCL

dimethylsulfoxide

10 mM

-20oC

Serine

Benzamidine

water

100 mM

-20oC

Cysteine

Iodoacetic acid

water

200 mM

Prepare fresh

Cysteine

E64-c

water

5 mM

-20oC

Leupeptin

water

10 mM

-20oC

Metallo

1,10 Phenanthroline

methanol

100 mM

RT3 or 4oC

Metallo

EDTA2

water

0.5 M

RT3 or 4oC

Acid Proteases

Pepstatin

DMSO

10 mM

-20oC

Aminopeptidase

Bestatin

water

5 mM

-20oC

Leupeptin

water

10 mM

-20oC

Thiol (serine & cysteine)

Threonine

1

PMSF is toxic. Weigh this compound in a fume hood, and wear appropriate personal protective

equipment.
2

Does not inhibit pancreatic elastase.

3

RT - Room Temperature.

Table 5: General protease inhibitor mix
Stock Inhibitor

Volume (µL)

PMSF (100 mM) or 3,4-DCI (10 mM) or Benzamidine (5 mM)

200

Iodoacetate (200 mM) or E64-c (5 mM)

200

1,10 phenanthroline (100 mM) or EDTA (500 mM) or Leupeptin (10 mM)

100

Pepstatin (10 mM)

100

Double Distilled Water

400

Final Volume

1,000

Table 6. Additional inhibitors that can be used to supplement protease inhibitor mixes.
Inhibitor

Solvent

Molarity

Storage

water

300 mM

-20oC (at pH 7)

DMSO

10 mM

-20oC

water

10 Units/mL

-20oC (at pH 7)

TLCK (Inhibits chymotrypsin-like serine proteases)

1 mM HCl

100 µM

Prepare fresh

TPCK (Inhibits chymotrypsin-like serine proteases)

Ethanol

10 mM

4oC

DIFP (Highly toxic cholinesterase inhibitor. Broad

anhydrous

200 mM

-20oC

spectrum serine protease inhibitor. Hydrolyzes rapidly in

isopropanol

water

10 mM

-20oC

water

100 mM

-20oC

water

100 mM

Prepare fresh

water

1 mM

-20oC

Serine Protease Inhibitors
Aprotinin (Does not inhibit thrombin or factor Xa)
Chymostatin (Inhibits chymotrypsin-like serine proteases
such as chymase cathepsins A,B,D and G. Also inhibits
some cysteine proteases such as papain)
Antithrombin III (Inhibits thrombin, kallikreins, plasmin,
trypsin and factors Ixa, Xa, and Xia)

aqueous solutions)
Antipain (Inhibits serine proteases such as plasmin,
thrombin and trypsin. Also inhibits some cysteine
proteases such as calpain and papain)
α2-Macroglobulin (Broad spectrum protease inhibitor)

Cysteine Protease Inhibitors
N-Ethylmaleimide

Metalloprotease Inhibitors
Phosphoramidon (Strong inhibitor of
metalloendoproteases, thermolysin and elastases, but a
week inhibitor of collagenase)

Table 7: Commonly used phosphatase inhibitors.
Name

Typical Working Molarity Range

Stock Molarity

Typical Inhibitory Targets.

p-Bromotetramisole

0.1 – 1.5 mM

100 mM

Alkaline Phosphatases (49, 50)

Cantharidin

20 – 250 μM

2.5 mM

Protein Phosphatase 2-A (49, 51)

Microcystin LR

20 – 250 nM

2.5 μM

Protein Phosphatase 1 and 2-A
(49, 52)

Imidazole

50 – 200 mM

1M

Alkaline Phosphatases (53, 54)

Sodium molybdate

50 – 125 mM

1M

Acid phosphatases and
Phosphoprotein Phosphatases
(51, 54)

Sodium orthovanadate

50 – 100 mM

1M

ATPase inhibition, Protein
Tyrosine Phosphatases,
Phosphate-transferring enzymes.
(54, 55)

Sodium tartrate

50 – 100 mM

1M

Acid Phosphatases (52, 54).

Table 8: Supplemental chemical/enzyme additions to protease inhibitor buffer (56).
Item and typical working

Advantages

Disadvantages

Uses / Typical Protease

concentration

Targets

2-mercaptoethanol (1 mM)

Reduction cysteine protease
activity.

Dithiothreitol (2 mM)

Reduction cysteine
proteinase activity. Low
odour.
Removal of metal ions
involved in proteolysis
impeding proteolysis

EDTA
(5 mM)

Thiourea
(2 M)

Proteolysis inhibitory
effects, in conjunction with
improved protein
solubilisation.
Useful in solubilising
membrane proteins

Detergents (e.g. SDS or
deoxycholate; 2 %v/v)

Unfolding of target proteins
containing disulphide
bridges
Unfolding of target proteins
containing disulphide
bridges
The chelating effect of
EDTA will affect the
structure of metalloproteins
and dramatically reduce the
purification of polyHistidine tagged proteins.
Thiourea is considered a
possible human carcinogen
and mutagen.

Cysteine Proteases

May activate some proteases

Serine proteases
General stabilization of
lysosomal membranes to
prevent protease leakage
Can be included in the cell
lysis buffer for optimal
efficiency.

Sucrose(2.5 mM) /Glycerol
(5-15 %v/v)

Stabilises proteins

May need to be removed by
dialysis

DNase
(100 U/mL)

Reduction in the crude lysate
viscosity.

Requires further incubation
step of 10 min at 4°C in the
presence of 10 mM MgCl2.

NH3••••••

Fragments resulting
• cleavage
from

•

Leu

Arg

Gly

Gly

Ser

Ser

Val

Val

Arg

Arg

Cysteine Proteases

Non-His tagged protein
targets or non-metalloprotein
targets.

General purpose protease
inhibitor.

Tyr

Gln

Ala

Lys

Tyr

Gln

Ala

Lys

Cys

•••••COOH
COOH•

•
•

Figure
1: The schematic depicts a peptide chain fragment, indicating where the chain will be
•
cleaved by trypsin. Trypsin cleaves at the carboxyl side of Arginine (Arg) and Lysine (Lys)
amino acids. The cleavage points are indicated by arrows. The amino acid fragments resulting •
from the cleavage are indicated.
•

•
•
•

